Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focusing on creating value for people living with neurology and immunology conditions.
UCB’s 90-year book is a goldmine to discover!
Twitter Feed
-
#Epilepsy is the most common serious neurological condition, affecting more than half a million people in the UK. That is why UCB is collaborating with @epilepsysociety to address this problem. https://t.co/p1Rr0oqLEO #ProudPartners #HarnessingGenetic
— UCB News (@ucb_news) 14.02.2019 -
Find out more about our new genomic partnership with the UK @epilepsysociety – which follows UCB’s commitment to invest £1 billion into the UK life-sciences sector over the next five years. https://t.co/p1Rr0oqLEO #StrongerTogether #HarnessingGenetics #
— UCB News (@ucb_news) 13.02.2019 -
Deletions or duplications in a person’s genome are important risk factors for epilepsy. By identifying these gene alterations, we could change the way #epilepsy is treated. Curious to learn more? Click here: https://t.co/p1Rr0oqLEO #StrongerTogether #Ha
— UCB News (@ucb_news) 13.02.2019
Highlights
At UCB, we take our responsibility to the planet very seriously.
UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to further strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. Discove more...
